Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Cell Rep ; 27(9): 2759-2771.e5, 2019 05 28.
Article in English | MEDLINE | ID: mdl-31141697

ABSTRACT

Loss of functional cardiomyocytes is a major determinant of heart failure after myocardial infarction. Previous high throughput screening studies have identified a few microRNAs (miRNAs) that can induce cardiomyocyte proliferation and stimulate cardiac regeneration in mice. Here, we show that all of the most effective of these miRNAs activate nuclear localization of the master transcriptional cofactor Yes-associated protein (YAP) and induce expression of YAP-responsive genes. In particular, miR-199a-3p directly targets two mRNAs coding for proteins impinging on the Hippo pathway, the upstream YAP inhibitory kinase TAOK1, and the E3 ubiquitin ligase ß-TrCP, which leads to YAP degradation. Several of the pro-proliferative miRNAs (including miR-199a-3p) also inhibit filamentous actin depolymerization by targeting Cofilin2, a process that by itself activates YAP nuclear translocation. Thus, activation of YAP and modulation of the actin cytoskeleton are major components of the pro-proliferative action of miR-199a-3p and other miRNAs that induce cardiomyocyte proliferation.


Subject(s)
Apoptosis Regulatory Proteins/metabolism , Biomarkers/metabolism , Cell Proliferation , MicroRNAs/genetics , Myocytes, Cardiac/cytology , Myocytes, Cardiac/metabolism , Actin Cytoskeleton , Animals , Animals, Newborn , Apoptosis Regulatory Proteins/genetics , Cofilin 2/genetics , Cofilin 2/metabolism , Female , Male , Rats , YAP-Signaling Proteins
2.
Nature ; 569(7756): 418-422, 2019 05.
Article in English | MEDLINE | ID: mdl-31068698

ABSTRACT

Prompt coronary catheterization and revascularization have markedly improved the outcomes of myocardial infarction, but have also resulted in a growing number of surviving patients with permanent structural damage of the heart, which frequently leads to heart failure. There is an unmet clinical need for treatments for this condition1, particularly given the inability of cardiomyocytes to replicate and thereby regenerate the lost contractile tissue2. Here we show that expression of human microRNA-199a in infarcted pig hearts can stimulate cardiac repair. One month after myocardial infarction and delivery of this microRNA through an adeno-associated viral vector, treated animals showed marked improvements in both global and regional contractility, increased muscle mass and reduced scar size. These functional and morphological findings correlated with cardiomyocyte de-differentiation and proliferation. However, subsequent persistent and uncontrolled expression of the microRNA resulted in sudden arrhythmic death of most of the treated pigs. Such events were concurrent with myocardial infiltration of proliferating cells displaying a poorly differentiated myoblastic phenotype. These results show that achieving cardiac repair through the stimulation of endogenous cardiomyocyte proliferation is attainable in large mammals, however dosage of this therapy needs to be tightly controlled.


Subject(s)
Death, Sudden, Cardiac/etiology , MicroRNAs/adverse effects , MicroRNAs/genetics , MicroRNAs/therapeutic use , Myocardial Infarction/genetics , Myocardial Infarction/therapy , Sus scrofa/genetics , Animals , Cell Proliferation/genetics , Heart/physiology , Heart/physiopathology , Male , MicroRNAs/administration & dosage , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Myocytes, Cardiac/cytology , Myocytes, Cardiac/metabolism , Regeneration/genetics
3.
Methods Mol Biol ; 1553: 41-53, 2017.
Article in English | MEDLINE | ID: mdl-28229406

ABSTRACT

In contrast to prenatal life, cardiomyocyte proliferation in mammals is rapidly blunted after birth; as a consequence, clinically significant cardiac regeneration does not occur in adulthood. Thus, the modulation of cardiomyocyte proliferation by gene transfer offers an invaluable opportunity to both understand the mechanisms regulating renewal of these cells in the fetus and identify novel strategies for myocardial repair.In this Chapter, we report an exhaustive protocol to isolate, culture, and manipulate the properties of neonatal ventricular rat cardiomyocytes by small RNA transfection or transduction with viral vectors based on the adeno-associated virus, which exhibit exquisite tropism for these cells. We also provide techniques to assess DNA synthesis and cell proliferation.


Subject(s)
Gene Transfer Techniques , Myocytes, Cardiac/metabolism , Transduction, Genetic , Animals , Aurora Kinase B/metabolism , Biomarkers , Cell Proliferation , Cell Separation , Cells, Cultured , Dependovirus/genetics , Female , Fluorescent Antibody Technique , Gene Expression , Genetic Vectors/genetics , Histones/metabolism , Male , Mice , MicroRNAs/genetics , Microscopy, Fluorescence , Myocytes, Cardiac/cytology , Rats , Transfection , Transgenes
4.
Circ Res ; 120(8): 1298-1304, 2017 Apr 14.
Article in English | MEDLINE | ID: mdl-28077443

ABSTRACT

RATIONALE: Recent evidence indicates that a few human microRNAs (miRNAs), in particular hsa-miR-199a-3p and hsa-miR-590-3p, stimulate proliferation of cardiomyocytes and, once expressed in the mouse heart using viral vectors, induce cardiac regeneration after myocardial infarction. Viral vectors, however, are not devoid of safety issues and, more notably, drive expression of the encoded miRNAs for indefinite periods of time, which might not be desirable in light of human therapeutic application. OBJECTIVE: As an alternative to the use of viral vectors, we wanted to assess the efficacy of synthetic miRNA mimics in inducing myocardial repair after single intracardiac injection using synthetic lipid formulations. METHODS AND RESULTS: We comparatively analyzed the efficacy of different lipid formulations in delivering hsa-miR-199a-3p and hsa-miR-590-3p both in primary neonatal mouse cardiomyocytes and in vivo. We established a transfection protocol allowing persistence of these 2 mimics for at least 12 days after a single intracardiac injection, with minimal dispersion to other organs and long-term preservation of miRNA functional activity, as assessed by monitoring the expression of 2 mRNA targets. Administration of this synthetic formulation immediately after myocardial infarction in mice resulted in marked reduction of infarct size and persistent recovery of cardiac function. CONCLUSIONS: A single administration of synthetic miRNA-lipid formulations is sufficient to stimulate cardiac repair and restoration of cardiac function.


Subject(s)
Genetic Therapy/methods , MicroRNAs/administration & dosage , Myocardial Infarction/therapy , Myocytes, Cardiac/metabolism , Regeneration , Ventricular Function, Left , Animals , Apoptosis , Cell Proliferation , Cells, Cultured , Disease Models, Animal , Female , Gene Expression Regulation , Injections , MicroRNAs/genetics , MicroRNAs/metabolism , Myocardial Infarction/genetics , Myocardial Infarction/metabolism , Myocardial Infarction/physiopathology , Myocytes, Cardiac/pathology , RNA Interference , Recovery of Function , Time Factors , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL